Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AGEN1571 + Balstilimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AGEN1571 | AGEN 1571|AGEN-1571 | AGEN1571 is a human monoclonal antibody that targets ILT2, potentially leading to increased pro-inflammatory cytokine secretion, immune cell activation, and enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2906). | ||
| Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05377528 | Phase I | AGEN1571 + Balstilimab + Botensilimab AGEN1571 + Botensilimab AGEN1571 + Balstilimab AGEN1571 | Study of AGEN1571 in Participants With Advanced Solid Tumors | Completed | USA | 0 |